<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340128</url>
  </required_header>
  <id_info>
    <org_study_id>j/423/2252</org_study_id>
    <secondary_id>29463</secondary_id>
    <nct_id>NCT04340128</nct_id>
  </id_info>
  <brief_title>Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)</brief_title>
  <official_title>Evaluation of Efficacy of Intra-lesional Injections of Glucantime Once Weekly in Comparison With Twice Weekly in the Treatment of Acute Anthroponotic Cutaneous Leishmaniasis (ACL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mashad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kerman University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      Anthroponotic Cutaneous Leishmaniasis (ACL) is a parasitic disease caused by Leishmania
      tropica, pentavalent antimonials (sodium stibogluconate and meglumine antimoniate) have been
      used as a standard treatment for leishmaniasis for last 80 years. Systemic antimonial
      injection is painful, toxic, not affordable and moreover is not always effective. Many
      different modalities are used to treat the disease with a limited success. Intra-lesional
      injections of antimonials are used for the treatment of patients with a few lesions but no
      data is available on the rate of efficacy. In this study the efficacy of intra-lesional
      injections of Glucantime weekly is compared with intra-lesional injections of Glucantime
      twice weekly.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete healing of the lesion(s)</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partiall cure</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Cutaneous Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-lesional injection of Glucantime once a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-lesional injection twice a week, 0.1/cm2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meglumine antimoniate</intervention_name>
    <description>Intra-lesional injection once a week, 0.1/cm2</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Glucantime</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meglumine antimoniate</intervention_name>
    <description>Intra-lesional injection twice a week, 0.1/cm2</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Glucantime</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parasitologically proven cases of CL based on positive smear and/or culture

          -  Otherwise healthy subjects on the basis of medical history.

          -  Age 9-70 years

          -  Willing to participate in the study and sign the informed consent (by the patient or
             his/her parent/guardian in case of younger than 18 years).

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Duration of lesion more than 6 months

          -  Number of lesions more than 4

          -  History of allergy to Glucantime

          -  Serious systemic illnesses (as judged by the physician)

          -  Participation in any drug trials in the last 60 days

          -  No indication for systemic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alireza Khatami, MD MSPH</last_name>
    <role>Study Director</role>
    <affiliation>Center for Research &amp; Training in Skin Diseases &amp; Leprosy, Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Khamesipour, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Research &amp; Training in Skin Diseases &amp; Leprosy, Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahdieh Bahrami, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kerman University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Hossein Ghoorchi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mashhad University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRTSDL</name>
      <address>
        <city>Tehran</city>
        <zip>14166</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <keyword>Anthroponotic Cutaneous Leishmaniasis</keyword>
  <keyword>L. tropica</keyword>
  <keyword>Meglumine antimoniate (Glucantime)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meglumine Antimoniate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

